The stock of Genprex Inc (NASDAQ: GNPX) has decreased by -4.06 when compared to last closing price of 0.75.Despite this, the company has seen a gain of 3.07% in its stock price over the last five trading days. prnewswire.com reported 2025-01-23 that Expects to Complete Enrollment of First 25 Patients in Phase 2 Expansion Study During Second Half of 2025 for Interim Analysis Acclaim-3 Study Has FDA Orphan Drug and Fast Track Designations AUSTIN, Texas, Jan. 23, 2025 /PRNewswire/ — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the first patient has been enrolled and dosed in the Phase 2 expansion portion of the Company’s Acclaim-3 clinical study of Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with Tecentriq® (atezolizumab) as maintenance therapy for patients with extensive stage small cell lung cancer (ES-SCLC). “We are excited to begin the Phase 2 expansion portion of Acclaim-3, which will determine the 18-week Progression Free Survival (PFS) rate of REQORSA and Tecentriq combination maintenance therapy,” said Mark Berger, MD, Chief Medical Officer at Genprex.
Is It Worth Investing in Genprex Inc (NASDAQ: GNPX) Right Now?
The 36-month beta value for GNPX is at -0.94. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for GNPX is 8.27M, and currently, shorts hold a 4.79% of that float. The average trading volume for GNPX on January 23, 2025 was 1.92M shares.
GNPX’s Market Performance
GNPX’s stock has seen a 3.07% increase for the week, with a -19.83% drop in the past month and a -52.22% fall in the past quarter. The volatility ratio for the week is 8.39%, and the volatility levels for the past 30 days are at 8.61% for Genprex Inc The simple moving average for the past 20 days is -10.40% for GNPX’s stock, with a -51.56% simple moving average for the past 200 days.
Analysts’ Opinion of GNPX
Many brokerage firms have already submitted their reports for GNPX stocks, with National Securities repeating the rating for GNPX by listing it as a “Buy.” The predicted price for GNPX in the upcoming period, according to National Securities is $7 based on the research report published on January 26, 2021 of the previous year 2021.
Noble Capital Markets, on the other hand, stated in their research note that they expect to see GNPX reach a price target of $5. The rating they have provided for GNPX stocks is “Outperform” according to the report published on April 29th, 2019.
GNPX Trading at -30.13% from the 50-Day Moving Average
After a stumble in the market that brought GNPX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -94.45% of loss for the given period.
Volatility was left at 8.61%, however, over the last 30 days, the volatility rate increased by 8.39%, as shares sank -21.98% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -57.99% lower at present.
During the last 5 trading sessions, GNPX rose by +1.43%, which changed the moving average for the period of 200-days by -76.33% in comparison to the 20-day moving average, which settled at $0.8047. In addition, Genprex Inc saw -15.28% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for GNPX
Current profitability levels for the company are sitting at:
- -985.8 for the present operating margin
- 0.64 for the gross margin
The net margin for Genprex Inc stands at -980.82. The total capital return value is set at -13.71. Equity return is now at value -325.11, with -221.01 for asset returns.
Currently, EBITDA for the company is -31.06 million with net debt to EBITDA at 0.07. When we switch over and look at the enterprise to sales, we see a ratio of 196.98. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.86.
Conclusion
In conclusion, Genprex Inc (GNPX) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
